AtaCor Medical, a San Clemente, CA-based medical device company, completed a $25M Series B financing.
The round was led by a corporate partner, with participation from Broadview Ventures and aMoon Fund as well as new investors Hatteras Venture Partners, Catalyst Health Ventures (CHV) and Longview Ventures, a Broadview affiliate. In conjunction with the funding, Darshana Zaveri, Managing Partner of Catalyst Health Ventures, and Jeff Terrell, Partner at Hatteras Venture Partners, will be joining AtaCor’s Board of Directors.
The company intends to use the funds to reach US and EU regulatory clearances for its novel extracardiac temporary pacing system as well as enhancing development efforts for additional extracardiac therapies.
Led by Rick Sanghera, CEO, AtaCor Medical develops a novel extracardiac pacing system designed to leave the heart and the vascular system without requiring any hardware to be placed inside or onto a patient’s heart. The technology has already completed early clinical evaluation and will offer an important alternative treatment option for patients requiring bradycardia pacing support. The extracardiac pacing system is being developed for temporary and permanent pacing markets and is not yet approved for sale in any geography.